Author(s)
Thomas Kehrer
Published 2 Projects
COVID-19 Biochemistry Infectious Diseases Key Words Sars Cov 2 Pl Protease
Daniel Stadlbauer
Published 9 Projects
COVID-19 Coronavirus SARS-CoV-2 Epidemiology Infectious Diseases
Viviana Simon
Published 15 Projects
Infectious Diseases Epidemiology Immunology Allergy And Immunology Nosocomial Outbreak
Adolfo García-Sastre
Published 9 Projects
COVID-19 Microbiology Biochemistry Infectious Diseases Allergy And Immunology
Content
The current COVID-19 (coronavirus disease 19) pandemic, caused by SARS-CoV-2, disproportionally affects the elderly and people with comorbidities like obesity and associated type 2 diabetes mellitus. Small animal models are crucial for the successful development and validation of antiviral vaccines, therapies and to study the role that comorbidities have on the outcome of viral infections. The initially available SARS-CoV-2 isolates require adaptation in order to use the mouse angiotensin converting enzyme 2 (mACE-2) entry receptor and to productively infect the cells of the murine respiratory tract. We have mouse-adapted SARS-CoV-2 by serial passaging a clinical virus isolate in the lungs of mice. We then used low doses of this virus in mouse models for advanced age, diabetes and obesity. Similar to SARS-CoV-2 infection in humans, the outcome of infection with mouse-adapted SARS-CoV-2 resulted in enhanced morbidity in aged and diabetic obese mice. Mutations associated with mouse adaptation occurred in the S, M, N and ORF8 genes. Interestingly, one mutation in the receptor binding domain of the S protein results in the change of an asparagine to tyrosine residue at position 501 (N501Y). This mutation is also present in the newly emerging SARS-CoV-2 variant viruses reported in the U.K. (20B/501Y.V1, B1.1.7 lineage) that is epidemiologically associated with high human to human transmission. We show that human convalescent and post vaccination sera can neutralize the newly emerging N501Y virus variant with similar efficiency as that of the reference USA-WA1/2020 virus, suggesting that current SARS-CoV-2 vaccines will protect against the 20B/501Y.V1 strain.
More Projects
Loren Frank
13 views • 2 years ago
Global Immunotalks
390 views • 2 years ago
Laurel Yohe
2 views • 2 years ago
Global Immunotalks
130 views • 2 years ago
Jignesh H. Parmar
0 views • 1 year ago
Winston A. Haynes
0 views • 1 year ago
Noam Mazor
0 views • 1 year ago
Global Immunotalks
182 views • 2 years ago
Cem Yuksel
345 views • 2 years ago
Oscar Gonzalez-Recio
3 views • 2 years ago
Please pick a style:
Florian Krammer. (2021, Oct 30).The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera[Video]. Scitok. https://scitok.com/project/p/cc906419
Rathnasinghe Raveen. "The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera" Scitok, uploaded by Krammer Florian, 30 Oct, 2021, https://scitok.com/project/pcc906419
Florian Krammer. "The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera" Scitok. (Oct 30, 2021). https://scitok.com/project/p/cc906419
Florian Krammer (Oct 30, 2021). The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera Scitok. https://scitok.com/project/p/cc906419
Florian Krammer. The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera[video]. 2021 Oct 30. https://scitok.com/project/p/cc906419
@online{al2006link, title={ The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera }, author={ Krammer, Florian }, organization={Scitok}, month={ Oct }, day={ 30 }, year={ 2021 }, url = {https://scitok.com/project/p/cc906419}, }